by Michael A. Goldman,* PhD, Professor & Former Chair, Biology, San Francisco State University (SFSU).
No engineer would build a bridge and gingerly drive over it today without first simulating the structure and its resilience using computer models. Why then should pharmaceutical companies test drugs in animals and people without sophisticated simulation first? Speaking at the virtual Precision Medicine World Conference (PMWC) 2021 (June 14-18) symposium on artificial intelligence and data science today (6/15/2021), Siddhartha Roychoudhury, PhD, Global Product General Manager at Amgen, says "Clinical trial design is still stuck in the 1970's."
Login Or Register To Read Full Story